Xadago

Safinamide (INN; brand name Xadago) is a drug used as an add-on treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.[2][3][4] It was approved in Europe in February 2015,[2] in the United States in March 2017,[3] and in Canada in January 2019.[5] Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Overd... [wikipedia]